Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma
Expert Review of Pharmacoeconomics & Outcomes Research · 17.08.2026 · 1-8
DOI: 10.1080/14737167.2026.2719622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 17.08.2026. Verfasst von Yu-Fan Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Postdoctoral Fellowship Program of CPSF, National Natural Science Foundation of China, Soaring Talent Development Program of Eastern Hepatobiliary Surgery Hospital.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
- The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Förderung
- Postdoctoral Fellowship Program of CPSF
- National Natural Science Foundation of China
- Soaring Talent Development Program of Eastern Hepatobiliary Surgery Hospital
- Natural Science Foundation of Fujian Province
- University-level Basic Medical Research Project of Naval Medical University
Zitieren
APA
Huang, Y. F., Qin, J. J., Wu, X. Q., Liu, H., Luo, S., & Xu, Z. Q. (2026). Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research, 1-8. https://doi.org/10.1080/14737167.2026.2719622
Vancouver
Huang YF, Qin JJ, Wu XQ, Liu H, Luo S, Xu ZQ. Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-8. doi:10.1080/14737167.2026.2719622
BibTeX
@article{Huang2026,
author = {Huang, Yu-Fan and Qin, Jia-Jing and Wu, Xiao-Qin and Liu, Hui and Luo, Susu and Xu, Zhe-Qi},
title = {Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
pages = {1--8},
doi = {10.1080/14737167.2026.2719622}
}
EUVIMED